MTN-036 was a Phase I study that evaluated two formulations of a ring designed to slowly release the antiretroviral drug dapivirine in the vagina over the course of 90 days, one containing 100 mg of dapivirine and the other containing 200 mg. Results, which were reported at the Conference on Retroviruses and Opportunistic Infections in 2021, found both formulations were well-tolerated and delivered target levels of drug throughout the three months of use, suggesting they may have the potential to provide long-acting and sustained HIV protection.
90-day dapivirine ring for women’s HIV prevention passes its first test in Phase I study
09-March-2021
See Also
MTN-036/IPM 047 Protocol